Viewing Study NCT03240393

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:07 AM
Ignite Modification Date: 2026-02-26 @ 5:17 PM
Study NCT ID: NCT03240393
Status: WITHDRAWN
Last Update Posted: 2018-07-26
First Post: 2017-07-26
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma View
None Non-Small-Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non Small Cell Lung Cancer View
None NSCLC View
None INC280 View
None EGFR wild-type (wt) View
None advanced non-small cell lung cancer View
None advanced/metastatic disease View
None Non-small cell lung carcinoma (NSCLC) View
None treatment of lung cancer after first metastasis View
None lung cancer View
None lung adenocarcinoma View
None Non small cell lung carcinoma View
None Non-small cell lung cancer View
None MET exon 14 deletion View
None MET exon 14 skipping View
None MET exon 14 mutation View
None MET mutation View
None MET amplification View
None MET inhibitor View
None MET dysregulation View
None MET activation View
None MET signaling View
None MET pathway View
None MET View
None cMET View